Social Media Wiki

Digital Marketing Lessons from 2011′s Top Memes

I love memes. They’re simple. They get one point across. They tend to be amusing.

I also like being “in the know” and there’s typically some backstory to the meme that you need to understand for it to make sense. It’s kind of like an exclusive club for the Internet set of us out there.

What I really like about memes is how you can use them to express a really simple concept.

For those of you who don’t really know what a meme is, here’s the official definition (thanks to Google’s handy “define” feature):

An element of a culture or system of behavior that may be considered to be passed from one individual to another by nongenetic means, esp. imitation

So, the key feature of a meme is really it’s ability to be passed along from one person to another. Sometimes it’s a joke and sometimes it’s a movement and something far more serious. However, when I look at a meme, I do something different than most people. I try to look for a lesson. I look for the one thing that I can learn from it. I also look at memes and figure out how I can use them to explain something else and to try to better understand human nature.

I’m weird like that.

This is what I’m doing today. I’m going to use the top memes of 2011 to review everything I witnessed as far as digital marketing trends in 2011. There will be plenty of lessons mixed in along the way. Chances are that you haven’t seen or heard of all of these memes (maybe none of them). You might not get some of the jokes, but I’ll do my best to explain them and I’ll point you to the good folks at Know Your Meme to give you even more detail if you want it.
(Click to read the rest…)

How Pharma Overcomplicates Social Media

I just finished a few days at Digital Pharma this week and it was a great conference. One of the trailblazers in pharma social media, Shwen Gwee, was the chair for the conference and, as an advisor, I got to watch him push for the best of the best content and format. It worked. If you want a great recap of what happened, head off to Twitter and pour through the stream for the conference’s hashtag, #digpharm.

I had seen and heard a lot of what was discussed at this meeting before simply because I get to spend a lot of my time thinking about it. For others that have a different focus in their day-to-day jobs, I’m sure they took away even more than I did. For me, the best part of the conference was the informal, “unconference” discussion that took place for the last two hours of the final day and was lead by Brad Pendergraph from Novartis. There was no stage, no slides, no official speakers, just a bunch of people really interested in digital pharma marketing talking to each other. It’s perhaps not surprising that the conversation almost exclusively focused on social media, as it seems like THE thing to talk about right now (and has for a while). The upcoming FDA hearings on this topic naturally make it more relevant and top of mind (PS: I’ve been invited to speak at the hearing and can’t wait to get in my two cents).

The participants of this final discussion were a good mix of pharma employees and agency/consultant types like me. I mostly listened to the conversation and took a few notes. At some point, I heard one of those simple statements that suddenly helps it all make sense. The “ah-ha” moment.

With constant debate of can we?/can’t we? in pharma companies when it comes to social media, I’ve been saying for a long time that we’re making it too complicated. While there are a lot of objections and concerns within pharma companies when it comes to social media, the one I hear most often and that really bugs me is about the internal regulatory/legal process. There are a lot of other objections that come up, but this one seems to particularly bother me. Here’s what I’m talking about. Let’s say your company starts a corporate blog and (imagine this) allows people to comment. Sure, moderate the comments if you’d like. No problem, just let through the legitimate ones.

Now, here’s where I get frustrated. Let’s say one of the comments is something of a question…something like this: “Great point, but don’t you think that [insert whatever ending you want]?” Clearly, it’s something that the person would like an answer to. They want to engage with you and have a discussion. It’s a great opportunity, right? You know that, so you decide to respond…and that’s when the wheels come off.

Since you’re going to create a response to publish, you have to send it through your review process. It takes a solid two weeks to do that using your normal channels. Or, maybe you’re lucky, you have an expedited process for this type of thing and you can get something out in a couple of days. Of course, by this time, the commenter probably has forgotten all about you. You likely missed a chance to make a major, positive impression. But why? Why did your response have to go through your whole process? “Well,” you say, “you know the answer to that Jonathan. If we post something online, then it has to through our regulatory process. Same rules as if we created a printed piece. What’s wrong with you…have you forgotten everything you learned working at a pharma company?” Okay, so maybe you’d leave out the last part, but you’d say the first part pretty much exactly as I wrote it.

“But, why?” I ask again. I have actually struggled to come up with a simple response to why you could justify NOT putting something like this through your official review process, but hadn’t come up with something yet. As pharma expands its social media efforts, at some point, this becomes a major issue. Are you going to review every tweet, every Facebook status update, and every “Hi, welcome to our forum” comment? You must either really love those regulatory meetings or you really have way too much spare time. Clearly, this isn’t going to be practical. At some point, you have to trust that people will do the right thing and follow the rules without reviewing every single thing they say before they say it.

Crazy…I know. Or is it? As I said, I struggled for a way to simply explain why this isn’t pure madness. It came to me while in the discussion at the conference. My epiphany came courtesy of Brad, who I mentioned earlier. He had the perfect analogy. I’m going to paraphrase just a bit, but here’s the gist:

When someone calls your company’s call center with a question about your product, do your representatives answer the question or do they tell the person that you’ll get back with them in 2-3 weeks?

Not to be outdone, Steve Woodruff, added to this (again paraphrasing):

When your reps are talking to a doctor and the doctor asks a question about your drug, does the rep have to pre-clear a response and get back with the doctor 2-3 weeks later?

Think about both of those statements for a minute. Obviously, we don’t make our call center representatives or sales reps wait for our regulatory process to review their answers before responding to a customer’s question, so why would we have to do this to respond to a customer question on our company blog? Do we trust our sales reps more than the person responsible for our blog? Do call center people get a special set of rules?

I don’t know the answers. I really don’t. You might argue (especially if you’re a lawyer), that the blog response  is “on paper” and therefore, more discoverable while the two analogies are just conversations that aren’t recorded. I suppose it would be harder to “get in trouble” if they aren’t recorded. Of course, this doesn’t put too much faith in your representatives to follow the rules and, the last time I checked, we had these things called voice recorders. If someone really wanted to get you in trouble, they could. Does anyone know the answer to this? I’m not saying that you should let every Tom, Dick, and Harry at your company respond to blog comments, but shouldn’t someone be allowed to do this without having everything approved before they say it?

One final comment that was said around this discussion came from Xavier Petit from Shire. His point related to the fact that we simply can’t ignore that people want to talk to us, so, basically, we have to respond when they come to us. We can’t just ignore them. His analogy was something like this (again, paraphrasing because I can’t write fast enough):

When we realized that people were going to call us on the phone when we gave out our number, did we suddenly decide to cut all the phone lines?

Of course not, but isn’t that what we’re doing when we don’t respond when someone asks us something via a social media channel? We create places for people to comment, but when we realize that they’ll actually do it, we cut off the communication. Actually, it’s exactly the same thing.

So, why are you still here? Shouldn’t you be calling your IT group and telling them to turn off the Internet?

Emerging Media in Healthcare and Pharma White Paper

After my recent post where I shared my white paper on “The Future of Digital Relationship Marketing in Pharma,” many of you inquired if I had any similar papers. You’re in luck. I have one that’s a different topic, but I think related.

This one is called: “Emerging Media in Healthcare and Pharma.”

Here’s a brief summary:

“There are a significant number of emerging media areas that will affect healthcare and pharmaceutical marketing campaigns in the future. Some will have an enormous positive impact on current marketing practices, while others will have devastating negative consequences on these same practices. The good news is that there are alternatives to the way many current campaigns are conducted that leverage the best in consumer understanding, interactive technologies, and solid marketing strategy (all while staying within DDMAC rules).”

I identified eight emerging media trends that about which I think every healthcare and pharma marketer should be aware:

  • Medical Social Networking: Beyond Facebook and MySpace, patients are now connecting with one another online and taking each other’s advice, sometimes over their physician’s advice.
  • Live and (Almost) in Person: YouTube is fine for delivering content, but it is instantly outdated. Consumers want to use video to interact with a real person to get the freshest information all from the comfort of their homes. This includes their doctors.
  • Secure Communications: People will begin to trust more of their confidential information online, but will expect that it be protected through constantly secure channels.
  • Micro-targeting: Targeting consumers has evolved dramatically in the past 10 years to the point where it is possible to find and communicate with a small group of brand supporters in a highly cost effective manner.
  • Instant, Dynamic Content: Online content must now immediately change based on user inputs. Providing the same content for everyone regardless of what they do on your site is a losing proposition.
  • Mobile Grows Up: Typically seen as a marketing platform that could only reach teenagers, older users are beginning to adopt some of the same habits as younger consumers, opening up a range of new promotional options.
  • Managing and Leading Word of Mouth: Tracking down everything that someone says about your brand was impossible without Internet-based technologies. Now brands are expected to track, and where appropriate, join in the conversations that people are having about them.
  • Print Goes Interactive: Print isn’t dead, but it needs to leverage interactive technologies to stay relevant and match consumer behaviors.

If you want more information on each of these trends, then you can download my full white paper on this topic: Emerging Media in Healthcare and Pharma  (1687 downloads)

As an added bonus, I want to share a copy of an article I had published in Pharmaceutical Executive last year called “Exercising Your Brand.” This paper outlines these rules healthcare marketers must follow to help ensure a successful digital program. I’ll share the link with you via DM on Twitter if you send this tweet about today’s post (PS: make sure you’re following me, so I can DM you). Deal?

If you want to be informed of any new white papers I publish, just fill out the form below. Your information will only be used for this purpose and will never be shared under any circumstance.

Note: Stay tuned for an updated version of this paper in the coming months. Emerging media changes quickly, so it’s difficult to stay current no matter how often you’re updating.

Why Pharma Needs Product Reviews

Dose of Digital Mini White Paper

We see them everyday on pretty much every site we visit…except for pharma. We often use them to make decisions about what products we buy and which we keep buying…except for pharma. We give our opinion to manufacturers, as the people who know what the product really does, to help them improve…except for pharma.

I’m talking about the product review. If you have bought anything online or researched a future purchase online, chances are that you referenced user-created product reviews. It’s becoming fairly standard practice for most companies, as they’ve come to realize that this is pretty much an expected feature among today’s consumer. But it wasn’t always this way. (note: I mentioned product reviews in my article “The Myth of Adverse Event Reporting.”)

One of the big reasons that product reviews were slow to appear for a long time is that companies were afraid of negative reviews. It turns out, of course, that simply having reviews can increase traffic, conversion rate, and average order value (see more detail here). In addition, negative reviews aren’t an issue so long as there aren’t only negative reviews.  Consider this situation. You’re checking out a product online and all the reviews are glowing. What do you think about that? You’d probably feel like the results might not be all that authentic. Instead, when there are negative reviews, it actually can lend credibility to the product (and site) because people know the reviews are actually genuine. Negative reviews don’t immediately turn people off. They read them and consider whether the negative would actually bother them. For example, someone ranks a product 1-star and says “this didn’t work on my Mac.” Well, if you have a PC, you aren’t worried. Simple example, but you see how it works.

AdAge just published an article about product reviews with a great title (good article, too): “Forget Twitter; Your Best Marketing Tool Is the Humble Product Review.” This title says it all. We’re talking an awful lot about Twitter lately, but let’s get back to the basics. Yes, it’s important to monitor Twitter to see what people are saying about your brand, but if you’re expecting some major insight or great new idea, you’re looking in the wrong place. AdAge quotes Sam Decker, CMO of Bazaarvoice, a” company that manages product-review platforms:” “His offline analogy is a room where everyone is there to talk about your product [product reviews] vs. a room where they are there to talk about anything [Twitter].” Tough to find the important conversations about a specific product in the latter.

Product reviews have become so mainstream and so important in brand consideration that many companies use product reviews received online in their offline advertising. Makes sense, right? If product reviews drive conversion rates and increase order values, why not advertise your reviews?  Best Buy was one of the first to do this. Bazaarvoice’s blog (company CMO quoted above) had a good article about this and reprinted this example picture of a Best Buy Sunday circular:

With all of this increased adoption of product reviews (and increased sales from them), are any pharma companies using product reviews on their sites? I haven’t found one, so please correct me if I missed one. I’ve seen content reviews, where users can rate thumbs up or thumbs down or assign a number of stars to a specific article or page, but not product reviews. At least, I haven’t seen them on pharma websites. But reviews of pharma products do exist. Meet iGuard. iGuard has user ratings on thousands of drugs including aggregated stats and comments. As an example, you can view the profile for Lipitor on iGuard here (registration required).  Here are some of the overall ratings for Lipitor:

Lipitor iGuard Reviews

But, how reliable is this information? The Lipitor ratings are based on 45,430 surveys sent out by iGuard (more on their process here). That’s a pretty good sample to me. iGuard also collects information about what patients wish they knew about the drug before they started. For Lipitor, 18% wish they were told more before starting treatment. iGuard used to include what specifically people wished they knew in the drug profiles, but it appears that they no longer post this information. My guess would be that they would be more than happy to sell you the information. This is a great opportunity to figure out what to include in future patient educational efforts.

There are also 80 comments (i.e., product reviews on the site). That’s going to tell you a lot about Lipitor. I’m going to warn you right now, the comments aren’t pretty overall and do include quite a few “adverse events,” but there are some great comments as well. Here’s a sample of each:

“I have taken lipitor for many years and have recently developed chronic inflammation of the pancreas and a triclycercide count of 636. I am not overweight at all, don’t drink, exercise and eat healthy. Can lipitor cause this.? [note: comment unedited]“

“I am a 62 year old female who with out this I can not walk to shop or any thing in my home that took any being on a step stool or walking in my home, now I can walk 8miles to do shopping, do the shopping & with a full 4 wheel personal cart walk back. [note: comment unedited]“

Yes, you will have to deal with adverse events if you go with product reviews. With a simple process, you can moderate every comment and deal with it appropriately. It’s ironic that pharma companies always cite this issue of adverse events when it comes to getting feedback from patients particularly when discussions about social media come up. However, at the same time, more and more companies are voluntarily adding links (which I bet will be required soon enough) to the FDA website and a phone number encouraging people to report adverse events directly to the FDA. This tells me that pharma companies aren’t necessarily afraid of what they might hear, but rather that they simply don’t want to deal with the information. That is, they don’t want to create a process to deal with it. But all these companies already have processes in place for adverse event reporting. An electronic version would flow quite simply into this. Also, keep in mind that you aren’t required to post every comment or review on your site. Those that are inappropriate (not just negative, but contain rants or foul language, for example) can be taken out. You simply need to ensure that you are transparent about your policy on how you moderate comments and which you post and which you don’t.

So, how is adding product reviews going to help you sell more of your product? One of the first things they teach you in sales and marketing is that a customer saying “no” to your sales pitch isn’t necessarily a bad thing. The reason why is because, with some questions, you can figure out why they aren’t interested, and deal with these issues. But going through all of this effort is very expensive. Just look at the budgets pharma companies allocate for field sales teams if you don’t agree. When it comes to pharma, or any industry, keeping your current customers is always cheaper than finding new ones. The people writing reviews on iGuard, for example, are already on your product. You’ve spent money on DTC TV, iMedia, the sales team, print ads, and a thousand other tactics, but now you’re about to lose them. Unless you don’t.

When comments are on a 3rd party site like iGuard instead of your own, you can’t be involved in the conversation. Imagine instead that they were on your site. This would allow you to do two things. Since you would require people to register to leave a comment (and you would), they also would provide their contact information. You can ask them if they’d like someone to contact them about their issue when they sign up. In this case, when someone posts a review saying they are having a certain side effect, you can do something to keep them on your product. Chances are that if this patient doesn’t get an answer, they’ll stop your treatment. So, you can have a nurse or other professional call and talk about the person’s issue. You can even go so far as to contact with the person’s doctor (with his or her permission) and explain the problem. The doctor can then follow up with appropriate actions like dosage adjustments, side effect management, or, where necessary, switching the patient to something different.

Think for a minute how this would be perceived by the medical community and patients. Wouldn’t doctors like to know when their patients are having a problem with their medication? As you know, patients aren’t always forthcoming with this information, as many simply stop treatment on their own before talking with their doctor. So wouldn’t this be a really valuable service? Wouldn’t this also give you an opportunity to talk with the doctor about your brands? I’m not saying you should “detail” the doctor when you make one of these calls, but you would be sharing relevant clinical data about the product during your conversation such as side effect rates and efficacy. This would certainly keep your products top of mind in a meaningful way. As for patients, they’d also find this service useful. Sometimes they don’t know how to communicate effectively with their doctors. Maybe you can bridge this gap.

This is one way that pharma companies can start doing Marketing with Meaning instead of trying to get people’s attention via interruptive  advertising that people are tuning out. It’s not without complications and it would take a unified effort across a number of different divisions in a pharma company to make this happen, but it would be worth it. The impact you could have on physicians and patients would be far larger than any investment and could go a long way to changing the perception of pharma in the public’s eye.

Older Posts »